Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors Following Disease Progression or Relapse

Maria Effrosyni Livanou,Vasiliki Nikolaidou,Vasileios Skouras,Oraianthi Fiste,Elias Kotteas
DOI: https://doi.org/10.3390/cancers16061196
2024-03-19
Cancers
Abstract:Immune checkpoint inhibitors (ICIs) are at the forefront of advanced non-small-cell lung cancer (NSCLC) treatment. Still, only 27–46% of patients respond to initial therapy with ICIs, and of those, up to 65% develop resistance within four years. After disease progression (PD), treatment options are limited, with 10% Objective Response Rate (ORR) to second or third-line chemotherapy. In this context, ICI rechallenge is an appealing option for NSCLC. Most data on the efficacy of ICI rechallenge are based on retrospective real-world studies of small, heavily pretreated, and heterogeneous patient groups. Despite these limitations, these studies suggest that ICI monotherapy rechallenge in unselected NSCLC patient populations who discontinued initial ICI due to PD is generally ineffective, with a median Progression-Free Survival (PFS) of 1.6–3.1 months and a Disease Control Rate (DCR) of 21.4–41.6%. However, there is a subpopulation that benefits from this strategy, and further characterization of this subgroup is essential. Furthermore, immunotherapy rechallenge in patients who discontinued initial immunotherapy following treatment protocol completion and progressed after an immunotherapy-free interval showed promising efficacy, with a DCR of 75–81%, according to post hoc analyses of several clinical trials. Future research on ICI rechallenge for NSCLC should focus on better patient stratification to reflect the underlying biology of immunotherapy resistance more accurately. In this review, we summarize evidence regarding rechallenge immunotherapy efficacy following NSCLC disease progression or relapse, as well as ongoing trials on immunotherapy rechallenge.
oncology
What problem does this paper attempt to address?
### What problems does this paper attempt to solve? This paper aims to evaluate the clinical efficacy of re - using immune checkpoint inhibitors (ICIs) in patients with non - small - cell lung cancer (NSCLC) after disease progression or recurrence. Specifically, the paper explores the following issues: 1. **Drug resistance after initial treatment**: Many advanced NSCLC patients will eventually develop drug resistance within four years despite an initial response after receiving ICI treatment. Therefore, the paper studies the effect of re - using ICIs in these patients after disease progression or recurrence. 2. **Efficacy differences in different populations**: The paper analyzes the efficacy differences in different subgroups of patients, especially the differences between those who relapse after a treatment - free period after completing the initial ICI treatment and those whose disease progresses during the treatment. 3. **Summary and evaluation of existing data**: The paper summarizes the effectiveness of ICI rechallenge therapy by reviewing the published data and points out the limitations of existing studies and the directions for future studies. 4. **Understanding of biological mechanisms**: The paper also explores the mechanisms of drug resistance after the initial ICI treatment, distinguishes between primary resistance and acquired resistance, and discusses the impact of these mechanisms on the efficacy of ICI rechallenge. ### Main findings - **Overall limited efficacy**: For unselected patient groups, ICI rechallenge is generally ineffective, with a median progression - free survival (PFS) of 1.6 to 3.1 months and a disease control rate (DCR) of 21.4% to 41.6%. - **Effective in specific subgroups**: For those patients who relapse after a treatment - free period after completing the initial ICI treatment, ICI rechallenge shows a better efficacy, with a DCR of up to 75% to 81%. - **Further stratification is required**: Future studies should focus on better stratifying patients to more accurately reflect the biological mechanisms of immunotherapy resistance. ### Keywords Immunotherapy, immune checkpoint inhibitors, rechallenge therapy, drug resistance, NSCLC Through these studies, the paper hopes to provide more evidence for clinicians to help them make more rational treatment decisions when facing NSCLC patients with disease progression or recurrence.